Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Can-Fite Biopharma Ltd
(NY:
CANF
)
2.360
USD
+0.150 (+6.79%)
Official Closing Price
Updated: 8:00 PM EST, Feb 24, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,724,900
Open
2.250
Bid (Size)
2.280 (1)
Ask (Size)
2.340 (17)
Prev. Close
2.210
Today's Range
2.180 - 2.490
52wk Range
1.100 - 2.980
Shares Outstanding
19,981,145
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson
February 22, 2021
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...
From
Business Wire News Releases
New Penny Stocks For Your February 2021 Watch List
February 02, 2021
Tags
Market News
From
Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Performance
YTD
+30.39%
+30.39%
1 Month
+12.92%
+12.92%
3 Month
+29.67%
+29.67%
6 Month
+0.85%
+0.85%
1 Year
+80.15%
+80.15%
More News
Read More
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
February 01, 2021
From
Business Wire News Releases
Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”
January 28, 2021
From
Business Wire News Releases
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers
January 08, 2021
From
Business Wire News Releases
Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs
December 15, 2020
From
Business Wire News Releases
Can-Fite Reports on Progress With Its Namodenoson NASH Program
December 14, 2020
From
Business Wire News Releases
Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows
February 22, 2021
Tags
FDA
Market News
Biotech
From
Benzinga
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?
February 22, 2021
From
PR Newswire
Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020
December 03, 2020
From
Business Wire News Releases
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
November 30, 2020
From
Business Wire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.